Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 25, 2014

View Archived Issues

Combination of GPR40 agonist and GLP-1 agonist improves glucose control in type 2 diabetes

WNT-974, a porcupine inhibitor targeting Wnt signaling in clinical testing

Candidate antidepressant mGlu2 and 3 receptor antagonists identified at Lilly

Development of a mouse model mimicking human ulcerative colitis

Paradigm to conduct genomic analysis to predict response to Tesaro's TSR-011

NuSirt Biopharma initiates phase II study of metformin/leucine combinations

Cardiac-selective sodium current inhibitor discovered at Gilead Sciences

ENSPIRIT trial of custirsen passes interim futility analysis

Heptares uses StaR platform to derive orexin receptor antagonists

Antitope and University College London to generate fully humanized antibodies

AbbVie begins phase I study of ABT-957 in subjects with Alzheimer's disease

Genentech begins phase I study of MOXR-0916 in locally advanced or metastatic solid tumors

Novel anti-HCV MAbs disclosed by Genentech

Researchers in Japan disclose humanized anti-HMGB1 MAbs

FDA grants Insys Therapeutics' cannabidiol orphan drug designation for GBM

Advaxis and Merck & Co. to collaborate on cancer immunotherapy combination trial

Nuvilex's cancer treatment evaluated in preclinical studies for malignant ascites

Enrollment open in phase I study of CB-5083 for relapsed/refractory multiple myeloma

Stanford University begins first-in-human study of Hu5F9-G4 for solid tumors

Vertex patents novel Na channel modulators

Naurex designs a new series of NMDA receptor modulators

DeuteRx divulges new deuterated PPAR-gamma agonists

Latuda launched in the U.K. for schizophrenia

Phase III REGULATE-PCI of Revolixys Kit halted

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...